EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Daptomycin-Induced Eosinophilic Pneumonia in a Patient Treated for MRSA Foot Infection: A Case Report

Ogechi Okafor, Julius Rey Angelo R Agorilla, Lee C Rogers iD

Journal of the American Podiatric Medical Association · 08.07.2026 · 116 (4) · 49

DOI: 10.3390/japma116040049 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of the American Podiatric Medical Association, online erschienen am 08.07.2026. Verfasst von Ogechi Okafor und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedics, The University of Texas at San Antonio, San Antonio, TX 78249, USA. Hauptthemen laut MEDLINE: Daptomycin, Pulmonary Eosinophilia, Anti-Bacterial Agents, Staphylococcal Infections. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Daptomycin is widely used for serious methicillin-resistant Staphylococcus aureus (MRSA) infections, but it can cause eosinophilic pneumonia, an uncommon and potentially severe adverse drug reaction. We report probable daptomycin-induced eosinophilic pneumonia (DIEP) in a 77-year-old woman receiving intravenous daptomycin with rifampin for a postoperative MRSA foot infection with concern for orthopedic-device involvement and osteomyelitis. Daptomycin had been initiated 10 days before admission, when she developed acute hypoxemic respiratory failure with bilateral ground-glass and consolidative opacities on chest computed tomography and a negative evaluation for infection. Daptomycin was discontinued on the day of admission, yet respiratory failure progressed, requiring mechanical ventilation. Bronchoalveolar lavage performed after corticosteroid exposure demonstrated eosinophilia (9%), and she improved with systemic corticosteroids and supportive care. Although she did not meet strict FDA “most likely/definite” criteria, the temporal association, compatible imaging, exclusion of alternative etiologies, abnormal lavage eosinophilia, and clinical response following drug withdrawal support “probable” DIEP criteria. Clinicians managing complex foot infections should consider DIEP when new respiratory symptoms and infiltrates develop during daptomycin therapy, even early in the treatment course and even when peripheral eosinophilia is absent or minimal.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DaptomycinPulmonary EosinophiliaAnti-Bacterial AgentsStaphylococcal InfectionsMethicillin-Resistant Staphylococcus aureusHumansFemaleAgedOsteomyelitis

Stichwörter der Autor:innen

MRSAdaptomycindiabetic foot infectiondrug-induced lung injuryeosinophilic pneumoniahardware infection

Substanzen

DaptomycinAnti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Orthopaedics, The University of Texas at San Antonio, San Antonio, TX 78249, USA.

ORCID-Profile: Lee C Rogers

Zitieren

APA

Okafor, O., Agorilla, J. R. A. R., & Rogers, L. C. (2026). Daptomycin-Induced Eosinophilic Pneumonia in a Patient Treated for MRSA Foot Infection: A Case Report. Journal of the American Podiatric Medical Association, 116(4), 49. https://doi.org/10.3390/japma116040049

Vancouver

Okafor O, Agorilla JRAR, Rogers LC. Daptomycin-Induced Eosinophilic Pneumonia in a Patient Treated for MRSA Foot Infection: A Case Report. Journal of the American Podiatric Medical Association. 2026;116(4):49. doi:10.3390/japma116040049

BibTeX
@article{Okafor2026,
  author = {Okafor, Ogechi and Agorilla, Julius Rey Angelo R and Rogers, Lee C},
  title = {Daptomycin-Induced Eosinophilic Pneumonia in a Patient Treated for MRSA Foot Infection: A Case Report},
  journal = {Journal of the American Podiatric Medical Association},
  year = {2026},
  volume = {116},
  number = {4},
  pages = {49},
  doi = {10.3390/japma116040049}
}
Kostenlos starten →